The Relationship between Clinical Feature, Complex Immunophenotype, Chromosome Karyotype, and Outcome of Patients with Acute Myeloid Leukemia in China

Table 2

Response to therapy in MPAL, Ly⁺AML, and Ly⁻AML patients [ (%)].

Group		Induction regimens/CR			CR after 2 courses	Postremission therapy			Relapse rate	Median time (Months)
		①	②	③		④	⑤	⑥		RFS	OS
MPAL	35	15 (42.8)/12 (80.0)	14 (40.0)/11 (78.6)	6 (17.1)/3 (50.0)	26 (74.2)	6 (23.1)	7 (26.9)	13 (50.0)	11 (42.3)	11	15
Ly^+AML	55	3 (5.5)/3 (100)	0/0	52 (94.5)/39 (75.0)	42 (76.4)	11 (26.2)	24 (57.1)	7 (16.7)	14 (33.3)	15	24
Ly^−AML	79	0/0	0/0	79 (100)/60 (75.9)	60 (75.9)	26 (43.3)	18 (30.0)	16 (26.7)	17 (28.3)	20	32
value	—	—	—	NS	NS	—	—	—	NS	<0.05^*	<0.05^*

Note. ① Induction treatment with combined AML/ALL drugs: DOALP (D: daunorubicin, O: vincristine, A: cytarabine, L: L-asparaginase, and P: prednisone) and DOAP. ② ALL-type induction therapy: VDLP (V: vincristine) and VDCP (c: cyclophosphamide). ③ AML-type induction therapy: DA/DAE/HA/TA (E: etoposide, H: homoharringtonine, and T: pirarubicin). ④ 3 courses of consolidation therapy and less than 3 courses of MD-Ara-C/HD-MTX. ⑤ Equal to or more than 3 courses of MD-Ara-C/HD-MTX or more than 3 courses of hyper-CVAD-A/B or autotransplantation after 5 median courses of standard-dose induction therapy, which ranges from 3 to 10 courses. ⑥ Allogeneic hematopoietic stem cell transplantation after 3–6 courses of consolidation or intensive therapy.
^*Statistical significant difference among MPAL, Ly⁺AML, and Ly⁻AML groups.
NS: no significance among MPAL, Ly⁺AML, and Ly⁻AML groups.